Suppr超能文献

抗逆转录病毒药物与 HIV 女性同群组患者抑郁症状的关联。

Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.

机构信息

Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

J Neuroimmune Pharmacol. 2021 Mar;16(1):181-194. doi: 10.1007/s11481-019-09899-2. Epub 2020 Jan 13.

Abstract

Antiretroviral therapy (ART) is inconsistently associated with depression. These associations may depend on factors such as biological sex, age, and health status. Identifying such factors may help optimize treatment of HIV and depression. We implemented a novel approach to examine interindividual variability in the association between ART agents and depressive symptoms. 3434 women living with HIV (WLWH) from the Women's Interagency HIV Study (WIHS) were computationally divided into subgroups based on sociodemographic (e.g., age) and longitudinal (from 1995 to 2016) behavioral and clinical profiles (e.g., substance use, HIV RNA, CD4 counts). Five subgroups (n's ranged from 482 to 802) were identified and characterized as those with: controlled HIV/vascular comorbidities; profound HIV legacy effects; younger women [<45 years of age] with hepatitis C; primarily 35-55 year olds; and poorly controlled HIV/substance use. Within each subgroup, we examined associations between ART agents used over the past 6 months and item-level depressive symptoms on the Center for Epidemiologic Studies Depression Scale. Tenofovir (4 of 5 subgroups) followed by efavirenz, emtricitabine, stavudine, lopinavir, etravirine, nelfinavir, ritonavir, and maraviroc were the most common agents associated with depressive symptoms, although the pattern and directionality varied by subgroup. For example, lopinavir was associated with fewer symptoms among the subgroup with a legacy HIV effect but more symptoms among the subgroup with well-controlled HIV/vascular comorbidities. Unexpectedly, dolutegravir and raltegravir were not associated with depressive symptoms among any subgroup. Findings underscore marked interindividual variability in ART agents on depression in WLWH. Sociodemographic, clinical, and behavioral factors are important determinants of the relationship between ART agents and depressive symptoms in WLWH. Graphical Abstract Are antiretroviral agents a risk factor for depressive symptoms in women with HIV? We examined associations between ART-agents and depressive symptoms among similar subgroups of women with HIV from the Women's Interagency HIV Study. The patterns of associations depended on sociodemographic, clinical, and behavioral characteristics of women.

摘要

抗逆转录病毒疗法(ART)与抑郁的相关性不一致。这些关联可能取决于生物学性别、年龄和健康状况等因素。确定这些因素可能有助于优化 HIV 和抑郁的治疗。我们采用了一种新方法来研究抗逆转录病毒药物与抑郁症状之间的个体间变异性。来自妇女艾滋病联合研究(WIHS)的 3434 名 HIV 感染者(WLWH)通过计算方法根据社会人口统计学(如年龄)和纵向(从 1995 年到 2016 年)行为和临床特征(如药物使用、HIV RNA、CD4 计数)分为亚组。确定了五个亚组(n 从 482 到 802 不等),并将其特征描述为:控制良好的 HIV/血管合并症;HIV 遗留效应显著;年龄较小的 HCV 感染女性(<45 岁);主要是 35-55 岁的人群;以及 HIV 控制不佳/药物使用的人群。在每个亚组内,我们检查了过去 6 个月内使用的 ART 药物与流行病学研究中心抑郁量表(Center for Epidemiologic Studies Depression Scale)的项目水平抑郁症状之间的关联。替诺福韦(五个亚组中的四个)随后是依非韦伦、恩曲他滨、司他夫定、洛匹那韦、依曲韦林、奈韦拉平、利托那韦和马拉维若,是与抑郁症状最相关的药物,尽管模式和方向因亚组而异。例如,洛匹那韦与 HIV 遗留效应亚组的症状较少有关,但与控制良好的 HIV/血管合并症亚组的症状较多有关。出乎意料的是,多替拉韦和拉替拉韦在任何亚组中都与抑郁症状无关。研究结果强调了 HIV 感染者中抗逆转录病毒药物对抑郁的个体间变异性。社会人口统计学、临床和行为因素是 HIV 感染者抗逆转录病毒药物与抑郁症状之间关系的重要决定因素。

相似文献

2
Associations between Antiretrovirals and Cognitive Function in Women with HIV.抗逆转录病毒药物与 HIV 女性认知功能的关联。
J Neuroimmune Pharmacol. 2021 Mar;16(1):195-206. doi: 10.1007/s11481-020-09910-1. Epub 2020 Mar 24.

引用本文的文献

本文引用的文献

6
Adverse events of raltegravir and dolutegravir.拉替拉韦和度鲁特韦的不良事件。
AIDS. 2017 Aug 24;31(13):1853-1858. doi: 10.1097/QAD.0000000000001590.
10
Tolerability of integrase inhibitors in a real-life setting.整合酶抑制剂在实际应用中的耐受性。
J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验